Cargando…

Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) most often develops in patients with underlying liver disease characterized by chronic nonresolving inflammation. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations within the tumoral microenvironment. As key actors of cancer-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Degroote, H., Van Dierendonck, A., Geerts, A., Van Vlierberghe, H., Devisscher, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206557/
https://www.ncbi.nlm.nih.gov/pubmed/30410942
http://dx.doi.org/10.1155/2018/7819520
_version_ 1783366370815115264
author Degroote, H.
Van Dierendonck, A.
Geerts, A.
Van Vlierberghe, H.
Devisscher, L.
author_facet Degroote, H.
Van Dierendonck, A.
Geerts, A.
Van Vlierberghe, H.
Devisscher, L.
author_sort Degroote, H.
collection PubMed
description Hepatocellular carcinoma (HCC) most often develops in patients with underlying liver disease characterized by chronic nonresolving inflammation. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations within the tumoral microenvironment. As key actors of cancer-related inflammation, they promote tumor growth by suppression of effective anticancer immunity, stimulation of angiogenesis, and tissue remodeling. Therefore, they have become an attractive and promising target for immunotherapy. The heterogeneity of TAM subtypes and their origin and dynamic phenotype during the initiation and progression of HCC has been partially unraveled and forms the base for the development of therapeutic agents. Current approaches are aimed at decreasing the population of TAMs by depleting macrophages present in the tumor, blocking the recruitment of bone marrow-derived monocytes, and/or functionally reprogramming TAMs to antitumoral behavior. In this review, the preclinical evolution and hitherto clinical trials for TAM-targeted therapy in HCC will be highlighted.
format Online
Article
Text
id pubmed-6206557
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62065572018-11-08 Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma Degroote, H. Van Dierendonck, A. Geerts, A. Van Vlierberghe, H. Devisscher, L. J Immunol Res Review Article Hepatocellular carcinoma (HCC) most often develops in patients with underlying liver disease characterized by chronic nonresolving inflammation. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell populations within the tumoral microenvironment. As key actors of cancer-related inflammation, they promote tumor growth by suppression of effective anticancer immunity, stimulation of angiogenesis, and tissue remodeling. Therefore, they have become an attractive and promising target for immunotherapy. The heterogeneity of TAM subtypes and their origin and dynamic phenotype during the initiation and progression of HCC has been partially unraveled and forms the base for the development of therapeutic agents. Current approaches are aimed at decreasing the population of TAMs by depleting macrophages present in the tumor, blocking the recruitment of bone marrow-derived monocytes, and/or functionally reprogramming TAMs to antitumoral behavior. In this review, the preclinical evolution and hitherto clinical trials for TAM-targeted therapy in HCC will be highlighted. Hindawi 2018-10-16 /pmc/articles/PMC6206557/ /pubmed/30410942 http://dx.doi.org/10.1155/2018/7819520 Text en Copyright © 2018 H. Degroote et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Degroote, H.
Van Dierendonck, A.
Geerts, A.
Van Vlierberghe, H.
Devisscher, L.
Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title_full Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title_fullStr Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title_full_unstemmed Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title_short Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
title_sort preclinical and clinical therapeutic strategies affecting tumor-associated macrophages in hepatocellular carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206557/
https://www.ncbi.nlm.nih.gov/pubmed/30410942
http://dx.doi.org/10.1155/2018/7819520
work_keys_str_mv AT degrooteh preclinicalandclinicaltherapeuticstrategiesaffectingtumorassociatedmacrophagesinhepatocellularcarcinoma
AT vandierendoncka preclinicalandclinicaltherapeuticstrategiesaffectingtumorassociatedmacrophagesinhepatocellularcarcinoma
AT geertsa preclinicalandclinicaltherapeuticstrategiesaffectingtumorassociatedmacrophagesinhepatocellularcarcinoma
AT vanvlierbergheh preclinicalandclinicaltherapeuticstrategiesaffectingtumorassociatedmacrophagesinhepatocellularcarcinoma
AT devisscherl preclinicalandclinicaltherapeuticstrategiesaffectingtumorassociatedmacrophagesinhepatocellularcarcinoma